Home Conferences Contact Us Continuing Education Jobs Weekly News Archives Readership Profile

Monthly News Archives Pharmacy Awards Search Site Search Magazine Archives Submit a Classified Advertisement



22 February 2002 News Update


New Zealand is one of the first countries in the world to announce approval of the Xeloda(capecitabine)/Taxotere(docetaxel) chemotherapy combination, a new chemotherapy regimen showing significantly superior survival in patients with metastatic breast cancer.

A global study showed that patients treated with Xeloda/Taxotere had a 23% improvement in median survival when compared to those treated with Taxotere alone.

For patients whose tumours have progressed despite first line chemotherapy treatment, the second line option of Xeloda and Taxotere may offer them an improved outcome. This means they now have a further option to discuss with their oncologist.

Back to welcome page

Back to news archives


Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here
For the answers to last month's quiz click here.


Click here to find out who the winners are for the Pharmacy Today/Zuellig Pharma Pharmacy Awards 2002. Also view and purchase photos of the Awards.


For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.


To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.

Job vacancies, items for sale, business opportunities and more.
Updated weekly.
click here.

Consumer Health Information

New Zealand Doctor Online